Scholars Central

Review articlePublished 10 Feb 2025

Exploring the Impact of Antihyperglycemic Agents on Diabetoporosis: An Updated Perspective

Authors: Ahmed Fawad, Muhammad Haris Sarwar, Zain Ahmar

Department of Otorhinolaryngology, Shalamar Hospital, Lahore, Pakistan

Clinical Pharmacology & Biopharmaceutics

Volume 14 · Issue 2 · Pages 1–6

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Diabetes mellitus is an enduring ailment that is swiftly spreading worldwide. Its repercussions are profound, significantly diminishing the quality of life by giving rise to numerous associated afflictions like kidney disease, cardiovascular conditions, obesity, and neurological disorders. Furthermore, it disrupts the metabolism of bones. Among the myriad complications accompanying diabetes, osteoporosis stands out as a prominent concern, often manifesting as a consequence of the disease. Both type-1 and type-2 diabetes bear a linkage to bone anomalies and an elevated susceptibility to fractures, making diabetes a recognized risk factor for osteoporosis. Consequently, there arises a need to scrutinize the potential therapeutic influence of hypoglycemic agents in addressing osteoporosis. The Glucagon-Like Peptide-1 (GLP-1) agonist, a class of hypoglycemic agents, emerges as a novel and promising candidate for osteoporosis management due to its additional involvement in the intricate process of bone remodeling. Studies suggest that GLP-1 agonists can bolster bone mineral density, enhance bone quality, and avert fractures in diabetic individuals. This comprehensive review spotlights recent discoveries concerning the utilization of antidiabetic medications in mitigating diabetes-induced osteoporosis. Additionally, it offers insights into the pathophysiology of this condition and the potential mechanisms that play a role in treating osteoporosis resulting from diabetes. Nevertheless, further research is imperative to gain a complete understanding of the therapeutic potential and distinctive mechanisms associated with GLP-1 agonists in the context of bone remodeling.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Pharmacology & Biopharmaceutics
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Ahmed Fawad”
  • BylineArticles whose byline prints “Muhammad Haris Sarwar”
  • BylineArticles whose byline prints “Zain Ahmar”